Zoledronic acid-associated osteonecrosis of maxilla
10.3760/cma.j.issn.1008-5734.2018.06.011
- VernacularTitle:唑来膦酸相关上颌骨坏死
- Author:
Yueli ZHANG
1
;
Wangjun QIN
1
;
Ang DENG
1
Author Information
1. 中日友好医院临床药学部,北京,100020
- Publication Type:Journal Article
- Keywords:
Osteonecrosis;
Maxilla;
Diphosphonates;
Zoledronic acid
- From:
Adverse Drug Reactions Journal
2018;20(6):446-447
- CountryChina
- Language:Chinese
-
Abstract:
An 81-year-old male patient received an IV infusion of zoledronic acid 4 mg once monthly for prostate cancer with bone metastasis in a local hospital. After 31 times of administration,the medication was given once every 3 months and after 3 times of treatment,the drug was stopped. The total accumulated dose of zoledronic acid was 136 mg. Two months after drug withdrawal,the patient developed pain in the left upper jaw when chewing food. He was diagnosed with endodontitis and 4 times of arrachement was performed in the local hospital. After the last operation,the wound did not heal with local pyorrhea and pain. The CT examination in China-Japan Friendship Hospital showed the osteonecrosis of left maxilla,which was considered to be related to zoledronic acid. Intravenous infusion of cefuroxime sodium 1. 5 g and metronidazole 0.5 g twice daily,and gargle with 0.02% chlorhexidine acetate solution 20 ml thrice daily were given. The patient underwent debridement of infection focus in left maxilla. The medications after the operation were as the same as before,except adding regional rinsing with 0.9% sodium chloride injection. On day 4 after operation,the local inflammation in left maxilla improved and 3 weeks later,the wound healed.
